Topical sucralfate cream treatment for aplasia cutis congenita with dystrophic epidermolysis bullosa: a case study


Yasar S., Yasar B., Cebeci F. C. , Bayoglu D., Nuhoglu C.

JOURNAL OF WOUND CARE, vol.27, no.11, pp.768-771, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 11
  • Publication Date: 2018
  • Doi Number: 10.12968/jowc.2018.27.11.768
  • Title of Journal : JOURNAL OF WOUND CARE
  • Page Numbers: pp.768-771

Abstract

Bart syndrome consists of aplasia cutis congenita (ACC) and dominant or recessive dystrophic epidermolysis bullosa (DEB), associated with skin fragility and nail dysplasia. ACC in DEB is thought to be caused by trauma, the most cited cause being in utero formation of bullae consequent to friction of the limbs. Epidermolysis bullosa (EB) refers to a hereditary mechanobullous disease following trauma, characterised by formation of blisters on the skin and mucous membranes. There are four categories of the disease, including epidermolysis bullosa simplex, junctional epidermolysis bullosa, dystrophic epidermolysis bullosa and Kindler syndrome. Infection, sepsis and death may occur as a consequence of generalised blistering with complication. We present the case of a newborn diagnosed with DEB and whose lesions became almost fully epithelialised after treatment with 10% topical sucralfate.